Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research. Over 2000 research labs worldwide (about 30% of global market share) and 50 hospitals have adopted Strand's genomics solutions today. These include leading clinical research, pharmaceutical and biotechnology organizations. With a highly skilled interdisciplinary workforce of more than 200 computer and life scientists, Strand has set up three clinical and translational research laboratories in Bangalore that are enabled with cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing personalized medicine to the world. For more information, please visit www.strandls.com
Milestones
2015
• Launched pan-cancer genomic profiling service in the US, powered by a state-of-the-art, CLIA certified lab at Colorado, USA in March 2015.
• Partnered with organisations across the globe to further the application of next-generation sequencing in research and diagnostics:
o March 2015: Announced partnership with MRI Global to set up reference laboratory in India to co-develop infectious disease diagnostics
oJune 2015: Announced cooperation with TATAA Biocenter, Sweden to distribute Strand NGS in Europe and offer NGS courses using Strand NGS
oJune 2015: Announced partnership with ReadSense, a Moscow-based genomics company to jointly develop affordable NGS-based diagnostic tests for neurological and primary immunodeficiency disorders
• Established contemporary genomics center offering genomics-based cancer diagnostics and genetic counselling services in hospitals across India
2014
• Received funding from Biomark Capital — a venture capital and private equity firm in healthcare and life sciences with its offices set in Moscow, San Francisco and Greenwich (USA)
• Received US patent protection in February 2014 for Virtual Liver model to predict htoxicity in rat and human liver (USPTO patent no. 8,645,075)
• Recognised by CIO Review as one of the 20 most promising tech solution providers to the Pharma and Life Science industries 2014
• Became a Member of 'Global Alliance for Genomics and Health'
• Announced collaborations with Triesta Sciences, a unit of HealthCare Global (HCG)and Sapien Biosciences for providing genetic based diagnostics services in HCG and Apollo hospitals across India
Milestones
2015
• Launched pan-cancer genomic profiling service in the US, powered by a state-of-the-art, CLIA certified lab at Colorado, USA in March 2015.
• Partnered with organisations across the globe to further the application of next-generation sequencing in research and diagnostics:
o March 2015: Announced partnership with MRI Global to set up reference laboratory in India to co-develop infectious disease diagnostics
oJune 2015: Announced cooperation with TATAA Biocenter, Sweden to distribute Strand NGS in Europe and offer NGS courses using Strand NGS
oJune 2015: Announced partnership with ReadSense, a Moscow-based genomics company to jointly develop affordable NGS-based diagnostic tests for neurological and primary immunodeficiency disorders
• Established contemporary genomics center offering genomics-based cancer diagnostics and genetic counselling services in hospitals across India
2014
• Received funding from Biomark Capital — a venture capital and private equity firm in healthcare and life sciences with its offices set in Moscow, San Francisco and Greenwich (USA)
• Received US patent protection in February 2014 for Virtual Liver model to predict htoxicity in rat and human liver (USPTO patent no. 8,645,075)
• Recognised by CIO Review as one of the 20 most promising tech solution providers to the Pharma and Life Science industries 2014
• Became a Member of 'Global Alliance for Genomics and Health'
• Announced collaborations with Triesta Sciences, a unit of HealthCare Global (HCG)and Sapien Biosciences for providing genetic based diagnostics services in HCG and Apollo hospitals across India
Location: India, Karnataka, Bengaluru
Employees: 201-500
Phone: +91 96866 01656
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Biomark Ca... | biomarkcap... |
| - | Quadria Ca... | quadriacap... |
Mentions in press and media 14
| Date | Title | Description |
| 11.09.2024 | Revolutionizing Cancer Diagnostics: The Promise of Liquid Biopsy and ecDNA Detection | In the realm of cancer diagnostics, innovation is the lifeblood. Two recent collaborations highlight a seismic shift in how we approach cancer detection and treatment. SOPHiA GENETICS, a leader in data-driven medicine, is at the forefront o... |
| 10.09.2024 | SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing | The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare tec... |
| 04.04.2024 | SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership | The companies will join forces to advance the use of precision medicine on a global scale BOSTON and ROLLE, Switzerland, April 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space a... |
| 09.02.2018 | Strand Life Sciences raises $13 Mn from Quadria Capital, Heritas Venture | Strand Life Sciences, a bioinformatics and diagnostics firm, has raised $13 million from Quadria Capital. The round also saw the participation of HealthQuad and Heritas Venture Fund. The fresh funding comes just after a month when Strand Li... |
| 08.02.2018 | Strand Life Sciences closes $13-million financing led by Quadria Capital | Strand Life Sciences announced an investment by Quadria Capital, Asia’s leading healthcare focused private equity investor. India-based HealthQuad Fund and Singapore-based Heritas Venture Fund also contributed to this investment. While the ... |
| 08.02.2018 | India: Strand Life Sciences raises up to $13m from Quadria Capital | Premium Strand Life Sciences, a bioinformatics and integrated and specialized diagnostics company, has raised Rs60-80 crore from private equity firm Quadria Capital, a senior executive of the firm said. Continue reading this story with a su... |
| 27.01.2016 | Venaxis Announces Transaction with Strand Life Sciences | CASTLE ROCK, Colo., January 26, 2016 /PRNewswire/ - Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders.... |
| 11.11.2015 | Other diagnostic companies utilize regulatory loopholes, not just Theranos | One benefit of the LDT loophole is the opportunity to keep methods secret – there’s no reason companies would need to publish data. “Their intellectual property is know-how and that’s something that they want to keep as trade secrets,” Mich... |
| 06.05.2015 | Exclusive: Strand Life Sciences close to raising $20M | Bangalore-based clinical genomics and biotech research firm Strand Life Sciences Pvt Ltd is close to raising $20 million (Rs 127 crore) from US-based investors, sources privy to the development told ... TO READ THE FULL STORY SUBSCRIBE LOGI... |
| 17.12.2013 | Curie-Cancer and Strand Launch Curie Image Database | PARIS and SAN FRANCISCO, December 17, 2013 /PRNewswire/ -- |
Show more